
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio Inc. has demonstrated significant progress in its gene therapy initiatives, particularly with dose level 2 showing robust microdystrophin expression and improved functional outcomes within 9 to 12 months, bolstering investor confidence in its ongoing research. The company's recent completion of the BLA submission for accelerated approval of clemidsogene lanparvovec (RGX-121) for MPS II positions it strategically for potential FDA approval in the second half of 2025, which would mark a significant milestone for both the company and the gene therapy landscape. Although Regenxbio reported a net loss of $51.2 million for the quarter, which was lower than projections, the overall revenue of $21.2 million reflects a consistent performance, highlighting the strength of its developmental pipeline and licensed programs despite external market influences.
Bears say
Regenxbio Inc. has reported declining revenues, with FY24 revenues at $83.3 million, a decrease from $90.2 million in the previous year, alongside a reduction in R&D expenses to $208.5 million from $232.3 million, suggesting potential challenges in its research initiatives. Additionally, the company's G&A expenses also fell to $76.6 million, down from $88.5 million, indicating ongoing cost management efforts. However, concerns regarding potential delays in data releases and insufficient manufacturing capacity could adversely affect sentiment and lead to downward revisions in financial forecasts, raising doubts about the company's growth prospects.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares